Ami Fadia, an analyst from Needham, maintained the Buy rating on Jazz Pharmaceuticals. The associated price target remains the same with $210.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ami Fadia has given his Buy rating due to a combination of factors, primarily driven by the promising results from the HERIZON-GEA trial involving Jazz Pharmaceuticals’ Ziihera. The trial demonstrated that Ziihera, when combined with chemotherapy, significantly improved progression-free survival (PFS) and showed a strong positive trend in overall survival (OS) compared to the control group. These results are particularly compelling as they surpass previous expectations and suggest that Ziihera-based treatments could become the new standard of care for first-line HER2+ locally advanced unresectable or metastatic gastric and esophageal adenocarcinoma (GEA).
Ami Fadia also notes the potential for a supplemental New Drug Application (sNDA) submission in the first half of 2026, which could further enhance Jazz Pharmaceuticals’ market position. The statistically significant improvements in both PFS and OS across different patient subgroups, including those with varying PD-L1 statuses, underscore the broad applicability and potential impact of Ziihera-based regimens. These developments, combined with the anticipation of further positive data from upcoming analyses, support the Buy rating for Jazz Pharmaceuticals.
In another report released on November 12, Bank of America Securities also reiterated a Buy rating on the stock with a $230.00 price target.